HC Wainwright Has Positive View of AC Immune FY2027 Earnings

Key Points

• HC Wainwright raised its FY2027 EPS estimate to $0.17 from $0.13 and projects FY2030 EPS of $1.65, a markedly more positive outlook versus the current consensus full-year estimate of ($0.69) per share.
• Analyst sentiment is mixed: two firms rate AC Immune a Buy, one a Hold and one a Sell, leaving an average consensus rating of Hold and an average price target of $7.50.
• Stock and recent results: ACIU trades around $3.05 with a 52-week range of $1.51–$4.00 and a market cap of ~$310M, and it recently reported a quarterly EPS of ($0.19) (beating estimates) with revenue of $1.4M (also above expectations).

AC Immune (NASDAQ:ACIU - Free Report) - Stock analysts at HC Wainwright raised their FY2027 earnings estimates for shares of AC Immune in a report issued on Monday, May 4th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.17 per share for the year, up from their previous forecast of $0.13. The consensus estimate for AC Immune's current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for AC Immune's FY2030 earnings at $1.65 EPS.

A number of other brokerages also recently commented on ACIU. Wall Street Zen raised AC Immune from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Weiss Ratings restated a "sell (d-)" rating on shares of AC Immune in a research note on Monday, April 20th. BTIG Research reiterated a "buy" rating and set a $8.00 target price on shares of AC Immune in a research note on Monday. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $7.00 price target on shares of AC Immune in a report on Friday, March 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $7.50.

AC Immune Stock Performance

NASDAQ:ACIU opened at $3.05 on Tuesday. AC Immune has a 52 week low of $1.51 and a 52 week high of $4.00. The firm has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $3.09. The firm has a market cap of $310.41 million, a price-to-earnings ratio of -3.72 and a beta of 1.66.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 110.92%. The business had revenue of $1.40 million during the quarter, compared to analysts' expectations of $0.33 million.

Institutional Trading of AC Immune

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its position in AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock valued at $679,000 after purchasing an additional 172,796 shares during the period. Sei Investments Co. bought a new position in shares of AC Immune during the second quarter valued at approximately $51,000. Private Advisor Group LLC purchased a new position in shares of AC Immune during the third quarter valued at approximately $48,000. Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the 3rd quarter worth approximately $63,000. Finally, Goldman Sachs Group Inc. increased its position in AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock valued at $58,000 after buying an additional 5,920 shares in the last quarter. Hedge funds and other institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.